Skip to main content

Table 1 Baseline characteristics of patients completing the milk programme

From: Changes in alanine aminotransferase in adults with severe and complicated obesity during a milk-based meal replacement programme

Parameters All patients Normal ALT High ALT P
N (%) 105 (100%) 57 (54.3%) 48 (45.7%)  
Female 56 (53.3%) 33 (57.9%) 23 (47.9%) 0.307
Age (years) 51.1 ± 11.2 52.9 ± 9.4 49.1 ± 12.8 0.079
Height (m) 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 0.502
Weight (kg) 144.0 ± 27.6 145.2 ± 27.3 142.6 ± 28.2 0.627
BMI (kg m2) 50.6 ± 8.0 51.5 ± 8.2 49.7 ± 8.0 0.254
EBW% 102.5 ± 32.0 106.0 ± 33.0 98.6 ± 31.2 0.254
ALTa (iu/L) 28.0 [20.0,40.5] 22.0 [17.0,24.5] 41.5 [34.3,63.5] < 0.0005
Total cholesterol (mmol/L) 4.6 ± 1.0 4.6 ± 1.0 4.6 ± 1.0 0.786
LDL (mmol/L) 2.5 ± 0.9 2.5 ± 0.9 2.6 ± 0.8 0.442
HDL (mmol/L) 1.2 ± 0.4 1.3 ± 0.4 1.2 ± 0.4 0.131
Triglyceride (mmol/L) 1.8 ± 0.8 1.7 ± 0.6 1.9 ± 1.0 0.151
Diabetes 37 (35.2%) 19 (33.3%) 18 (37.5%) 0.656
HbA1c (mmol/mol) 48.2 ± 15.6 48.1 ± 16.3 48.4 ± 15.0 0.943
Medications
Metformin 38 (36.2%) 22 (38.6%) 16 (33.3%) 0.576
Insulin 10 (9.5%) 7 (12.3%) 3 (6.3%) 0.294
SU 15 (14.3%) 10 (17.5%) 5 (10.4%) 0.298
DPP4 9 (8.6%) 6 (10.5%) 3 (6.3%) 0.436
SGLT2 6 (5.7%) 3 (5.3%) 3 (6.3%) 0.828
GLP1 18 (17.1%) 9 (15.8%) 9 (18.8%) 0.688
PPARG 1 (1%) 1 (1.8%) 0.356
ARBs 25 (23.8%) 12 (21.1%) 13 (27.1%) 0.470
ACEIs 30 (28.6%) 19 (33.3%) 11 (22.9%) 0.239
Beta blockers 31 (29.5%) 17 (29.8%) 14(29.2%) 0.914
Alpha blockers 6 (5.7%) 3 (5.3%) 3 (6.3%) 0.828
Diuretics 31 (29.5%) 15 (26.3%) 16 (33.3%) 0.432
Ezetemibe 4 (3.8%) 2 (3.4%) 2 (4.2%) 0.861
  1. Values are presented as Mean ± SD
  2. Comparisons between groups were made using Independent samples t test for normally distributed data, and Mann–Whitney U test for non-normally distributed data
  3. Proportions with categorical variables were compared using Pearson’s Chi-square test
  4. BMI Body Mass Index, EBW% Excess Body Weight Percentage, ALT Alanine Aminotransferase, LDL Low Density Lipoprotein, HDL High Density Lipoprotein, HbA1c Glycated haemoglobin, SU Sulfonylureas, DDP4 Dipeptidyl peptidase-4 inhibitors, SGLT2 Sodium-glucose co-transporter 2 inhibitors, GLP1 Glucagon-like peptide 1, PPARG Peroxisome proliferator-activated receptor gamma, ARBs Angiotensin II receptor blockers, ACEIs Angiotensin-converting enzyme inhibitors
  5. aDenotes variables that are not normally distributed, presented as median [IQR]